Trials / Completed
CompletedNCT01521767
Pharmacokinetics and Relative Bioavailability Study
A Single-Dose Pharmacokinetics And Relative Bioavailability Study Of Tolterodine From Two Microspheres In Powder Blend Extended Release Formulations Compared To The Commercial Extended Release Capsules
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 21 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A Single-Dose Pharmacokinetics And Relative Bioavailability Study Of Tolterodine From Two Microspheres In Powder Blend Extended Release Formulations Compared To The Commercial Extended Release Capsules
Detailed description
Pharmacokinetics And Relative Bioavailability Study Of Tolterodine From Two Microspheres In Powder Blend Extended Release Formulations Compared To The Commercial Extended Release Capsules
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tolterodine tartrate | 4 mg single dose of extended release capsules |
| DRUG | tolterodine tartrate | 4 mg single dose of microspheres in powder blend |
| DRUG | tolterodine tartrate | 4 mg single dose of microspheres in powder blend |
| DRUG | tolterodine tartrate | 4 mg single dose of microspheres in powder blend |
| DRUG | tolterodine tartrate | 4 mg single dose of microspheres in powder blend |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2012-01-31
- Last updated
- 2021-01-27
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT01521767. Inclusion in this directory is not an endorsement.